Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

23.12
-0.3100-1.32%
Post-market: 23.120.00000.00%19:30 EDT
Volume:511.97K
Turnover:11.76M
Market Cap:1.53B
PE:-7.43
High:23.51
Open:23.35
Low:22.61
Close:23.43
52wk High:30.99
52wk Low:10.30
Shares:66.17M
Float Shares:36.76M
Volume Ratio:1.03
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1097
EPS(LYR):-2.5230
ROE:-41.01%
ROA:-26.14%
PB:3.26
PE(LYR):-9.16

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 23

Bicara Therapeutics CEO Claire Mazumdar disposed of USD 282,000 in common shares

Reuters
·
Mar 21

Bicara Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview

Reuters
·
Mar 20

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 20

Bicara Therapeutics President and COO Ryan Cohlhepp disposes of USD 245,714 in common shares

Reuters
·
Mar 18

Bicara Therapeutics CEO Claire Mazumdar Disposes of Common Shares

Reuters
·
Mar 12

Bicara Therapeutics CEO Claire Mazumdar Disposes of Common Shares

Reuters
·
Mar 07

Bicara Therapeutics CFO Ivan Hyep Disposes of Common Shares

Reuters
·
Mar 06

Bicara Therapeutics Chief Medical Officer David Raben Disposes of Common Shares

Reuters
·
Mar 06

Why Bicara Therapeutics (BCAX) Is Up 10.3% After US$150 Million Follow-On Offering For Lead Drug

Simply Wall St.
·
Mar 04

Bicara Therapeutics announces inducement grants

TIPRANKS
·
Mar 04

BRIEF-Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Mar 04

Bicara Therapeutics Grants New Hire Stock Option for 115,000 Shares Under 2026 Inducement Plan

Reuters
·
Mar 04

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 04

Major Insider Move Signals Growing Confidence in Bicara Therapeutics

TIPRANKS
·
Mar 03

RA Capital Management Reports Acquisition of Bicara Therapeutics Common Shares

Reuters
·
Mar 03

Bicara Therapeutics President and COO Ryan Cohlhepp Disposes of Common Shares

Reuters
·
Feb 28

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

THOMSON REUTERS
·
Feb 27